In today’s scenario business development and licensing is integral to a company’s inorganic portfolio expansion and plugging the portfolio gaps.

We at MedDx support companies in identifying the best fit from the perspective of most attractive asset/MoA, commercial potential and partnerability using proprietary prioritization matrix which is different for early vs. late stage assets, it evaluates the assets on various clinical and commercial parameters, overlayed with strategic considerations.